Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer

Ken Suzawa, Michael Offin, Adam J. Schoenfeld, Andrew J. Plodkowski, Igor Odintsov, Daniel Lu, William W. Lockwood, Maria E. Arcila, Charles M. Rudin, Alexander Drilon, Helena A. Yu, Gregory J. Riely, Romel Somwar, Marc Ladanyi

Research output: Contribution to journalArticle

9 Citations (Scopus)
Original languageEnglish
JournalJCO Precision Oncology
Volume3
DOIs
Publication statusPublished - 2019

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Suzawa, K., Offin, M., Schoenfeld, A. J., Plodkowski, A. J., Odintsov, I., Lu, D., Lockwood, W. W., Arcila, M. E., Rudin, C. M., Drilon, A., Yu, H. A., Riely, G. J., Somwar, R., & Ladanyi, M. (2019). Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer. JCO Precision Oncology, 3. https://doi.org/10.1200/PO.19.00011